Results of Operations and Financial Condition. On August 3, 2026 , GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the quarter ended June 30, 2026 . Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 hereto, s…

President — Mark Gardner: The company appointed Mark Gardner as President, overseeing lab and commercial operations.

Results of Operations and Financial Condition. Financial Results for the Quarter Ended March 31, 2026 On May 4, 2026 , GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the quarter ended March 31, 2026 . Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.3, respectively, to this Current Report on Form 8-K. Consolidated Statements of Operation…

Termination of a Material Definitive Agreement. The information provided in

Entry Into a Material Definitive Agreement. Loan Agreement On February 27, 2026 (the “Closing Date”), GeneDx Holdings Corp. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”), with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. (collectively, the “Blackstone Representative” and referred to herein as “Blackstone”), certain subsidiaries of the Company party thereto as Guarantors, Wilmington Trust, National Association, as Agent and the l…

Cautionary Statement Regarding Forward-Looking Statements This Report contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the Loan Agreement and the transactions contemplated thereby, and the use of proceeds of the Term Loan. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “shoul…

Results of Operations and Financial Condition. On February 23, 2026 , GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the year ended December 31, 2025 . Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 heret…

Results of Operations and Financial Condition. The information set forth in

Results of Operations and Financial Condition. On October 28, 2025 , GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the quarter ended September 30, 2025 . Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 he…

Class I director on the Board — Thomas Fuchs, Dr.sc.: Dr. Thomas Fuchs was appointed as a Class I director on the Board of GeneDx Holdings Corp.

Results of Operations and Financial Condition. On July 29, 2025 , GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the quarter ended June 30, 2025 . Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 hereto, sh…

Results of Operations and Financial Condition. On April 30, 2025 , GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the quarter ended March 31, 2025 . Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 hereto,…

Entry into a Material Definitive Agreement On April 15, 2025, GeneDx Holdings Corp., a Delaware corporation (the “Company,” “we,” “us” and “our”), entered into an Agreement and Plan of Merger, dated as of April 15, 2025 (the “Merger Agreement”), by and among the Company, Project Flare Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and a wholly-owned subsidiary of the Company, Fabric Genomics, Inc., a Delaware corporation (“Fabric Genomics”), and Martin Reese, as the Agent, pursuant t…

Unregistered Sale of Equity Securities The information contained in

Results of Operations and Financial Condition. On February 18, 2025 , GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the year ended December 31, 2024 . Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 heret…

Results of Operations and Financial Condition. The information set forth in

Chief Operating Officer — Bryan Dechairo, Ph.D.: Dr. Bryan Dechairo was appointed as the new Chief Operating Officer with significant responsibilities and a comprehensive compensation package.

Results of Operations and Financial Condition. On October 29, 2024 , GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the quarter ended September 30, 2024 . Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 he…

Results of Operations and Financial Condition. On July 30, 2024 , GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the quarter ended June 30, 2024 . Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 hereto, sh…

Entry into a Material Definitive Agreement On April 29, 2024, GeneDx Holdings Corp. (the “Company”), entered into a sales agreement (the “Sales Agreement”) with TD Securities (USA) LLC, as sales agent and/or principal (“TD Cowen”), pursuant to which the Company may offer and sell, from time to time to or through TD Cowen, shares of the Company’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), having an aggregate offering price of up to $75.0 million (the “Share…

Results of Operations and Financial Condition. On April 29, 2024 , GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the quarter ended March 31, 2024 . Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 hereto,…

Results of Operations and Financial Condition. On February 20, 2024, GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the year ended December 31, 2023. Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 hereto,…

Results of Operations and Financial Condition. The information set forth in

Unregistered Sale of Equity Securities. The information required by this

Results of Operations and Financial Condition. On October 30, 2023, the Company issued a press release (the “Press Release”) announcing the Company’s financial results for the nine months ended September 30, 2023. The Company will hold a conference call to discuss its financial results for the nine months ended September 30, 2023 on October 30, 2023 at 4:30 p.m. ET. Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Rep…